Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
26.65
USD
+7.68%
+14.62%
+28.86%
Presentation Operator MessageOperator (Operator)Good morning, everyone, and welcome to the Sel...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target
Apr. 23
MT
Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement
Mar. 14
CI
Cartesian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 07
CI
Cartesian Therapeutics, Inc. Announces Resignation of Aymeric Sallin as Member of the Board of Director and Member of Compensation Committee
Mar. 05
CI
Cartesian Therapeutics, Inc. Establishes New Corporate Headquarters and mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
Mar. 05
CI
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
Jan. 08
CI
Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) dropped from NASDAQ Biotechnology Index
Dec. 15
CI
Cartesian Therapeutics, Inc. Announces Resignation of Scott D. Myers as Member of the Board, Compensation and Nominating and Corporate Governance Committees
Nov. 27
CI
North American Morning Briefing : Stock Futures -2-
Nov. 16
DJ
Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) added to NASDAQ Biotechnology Index
Nov. 15
CI
Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) added to NASDAQ Composite Index
Nov. 15
CI
Cartesian Therapeutics, Inc. announced that it has received $60.249953 million in funding
Nov. 14
CI
Selecta Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 13
CI
Sector Update: Health Care Stocks Gain in Late Afternoon Trading
Nov. 13
MT
Selecta Biosciences Merges With Cartesian Therapeutics
Nov. 13
MT
Transcript : Cartesian Therapeutics, Inc., Selecta Biosciences, Inc. - M&A Call
Nov. 13
Cartesian Therapeutics, Inc. acquired Selecta Biosciences, Inc. for approximately $380 million, in a reverse merger transaction.
Nov. 12
CI
Cartesian Therapeutics, Inc. announced that it expects to receive $60.249876 million in funding
Nov. 12
CI
North American Morning Briefing : Traders Await -2-
Nov. 09
DJ
Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement
23-10-31
CI
Peter Traber, Selecta Biosciences, Inc.?s Chief Medical Officer, Moves to Part-Time Status as Chief Medical Officer, Effective as of November 6, 2023
23-10-31
CI
North American Morning Briefing : Focus Shifts to -2-
23-08-21
DJ
Mizuho Trims Price Target on Selecta Biosciences to $3 From $4, Maintains Buy Rating
23-08-18
MT
Needham Adjusts Price Target on Selecta Biosciences to $4 From $5, Maintains Buy Rating
23-08-18
MT
Transcript : Selecta Biosciences, Inc., Q2 2023 Earnings Call, Aug 17, 2023
23-08-17
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
More about the company
Last Close Price
26.65
USD
Average target price
56.25
USD
Spread / Average Target
+111.07%
Consensus
1st Jan change
Capi.
+28.86% 474M +7.52% 113B +11.38% 106B +0.58% 22.27B -12.64% 22.22B -4.04% 19.43B -37.85% 17.87B -8.58% 17.24B +7.77% 14.29B +37.41% 12.52B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**